Delcath's ($DCTH) year of disappointment lumbers on as the New York company axes 21 of its 60 employees, looking to cut costs as it figures out just what to do with an FDA-rejected device. Last month, the agency finally closed the door on Melblez, a drug-device combo designed to treat eye cancer that has spread to the liver, which came as little shock to anyone paying attention. The FDA demanded another randomized clinical trial for the combo, likely postponing an approval date by years, and Delcath summarily fired CEO Eamonn Hobbs, appointing two of its executive vice presidents to serve as co-CEOs as it decides how to proceed with the FDA. Story